- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Meeting Date: September 2021
- Public Summary Document (PSD) September 2021 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) September 2021 PBAC Meeting - (Word 942KB)
Tafamidis – September 2021
Tafamidis: Capsule 61 mg; Vyndamax®
Last updated
24 December 2021